For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Revenue | 0 | |||
| Research and development | 142,015,000 | |||
| General and administrative | 86,501,000 | |||
| Restructuring | 3,231,000 | |||
| Total operating expenses | 231,747,000 | |||
| Loss from operations | -231,747,000 | |||
| Interest expense | 1,891,000 | |||
| Interest and other income, net | 3,218,000 | |||
| Accretion of discount on investments, net | 7,297,000 | |||
| Net loss | -223,123,000 | |||
| Basic EPS | -2.01 | |||
| Diluted EPS | -2.01 | |||
| Basic Average Shares | 111,123,770 | |||
| Diluted Average Shares | 111,123,770 | |||
ROCKET PHARMACEUTICALS, INC. (RCKTW)
ROCKET PHARMACEUTICALS, INC. (RCKTW)